Successfully transferring manufacturing processes for advanced therapeutics and complex biologics requires a deep understanding of the modality-specific variables that define success. Applying proven intelligence in vector process development and analytics is how we accelerate next-generation therapies from the lab to GMP-compliant production, minimizing clinical risk at every stage.

Phase-Appropriate Process Development for GMP Readiness

The transition from preclinical development to a GMP environment introduces significant technical and regulatory hurdles. A process that performs well at the bench scale may not be robust or scalable enough for clinical manufacturing. This gap is often magnified for viral vectors, where minor deviations in upstream or downstream processes can impact vector identity, purity, and potency. Our approach focuses on de-risking this transition by establishing a well-characterized, phase-appropriate process before initiating a formal technology transfer.

Execution of Modality-Specific Technology Transfer Protocols

Our scientific teams function as an embedded extension of your own, ensuring continuity and knowledge preservation. We focus on the granular details that underpin a successful transfer.

• Process Characterization: We define key and critical process parameters (KPPs and CPPs), critical quality attributes (CQAs) and critical raw material attributes for AAV, lentivirus, and adenovirus vectors to establish a reproducible operational strategy.
• Analytical Assay Transfer: Potency, identity, and purity assays are transferred and qualified under GLP conditions, ensuring the methods used to release your product are robust and reliable.
• Documentation and Batch Records: We develop comprehensive documentation packages, including master batch records and SOPs, that are purpose-built for GMP compliance and regulatory submissions.

Mitigating Manufacturing Variability in Clinical Evaluation

When a vector product is well-characterized and consistently produced, it removes manufacturing variability as a confounding factor in clinical outcomes. This allows program sponsors to focus on the inherent biology of their asset, confident that the product itself is not introducing uncontrolled variables into preclinical or clinical evaluations.